Englewood Lab Reports Strong Q1 Growth, Dividend and Major Shareholder Stake Increase

Consolidated Q1 2026 revenue: $33.95M (up 16.0% YoY from $29.28M), operating profit $3.82M, net income $4.82M (up 115.8% YoY from $2.23M), EPS $0.24.
FY2025 cash dividend declared: approximately $2.8M (approx. ₩4.24 billion).
No current share buyback or cancellation plans.
Major shareholder Cosmecca Korea increased stake from 50.00% to 66.67% via public tender offer.
Bylaws amended to increase independent director ratio from at least 1/4 to at least 1/3, effective July 23, 2027.